Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in Advanced Solid Tumors and Multiple Myeloma
NCT02609230Phase 1Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Nov 2015
- Primary completion
- Mar 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dordaviprone in solid tumor (advanced stage) and multiple myeloma (MM) (2 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Nov 2015; status: completed.
02
Drugs
dordaviprone
03
Conditions
solid tumor (advanced stage)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02609230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609230.